Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06170619 · ClinicalTrials.gov registry record
Obsidio™ Conformable Embolic Registry
A clinical trial of Bleeding and Hemorrhage, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 125
- Enrollment target
- 20
- Study locations
NCT06170619: Completed study of Bleeding and Hemorrhage, sponsored by Boston Scientific Corporation.
NCT06170619 is a study of Bleeding and Hemorrhage that has completed, run by Boston Scientific Corporation. The registered enrollment target is 125 participants, below the 1,479-participant average among 23 other Bleeding trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06170619, a study of Bleeding and Hemorrhage, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Primary Outcome
The primary effectiveness endpoint is technical success, which is defined as occlusion of the target vessel(s) after embolization with Obsidio™ Conformable Embolic as assessed via angiography or demonstration of a cast of Obsidio occluding the artery on fluoroscopy or image acquisition immediately following the index procedure.
Conditions Studied
Interventions
- DEVICE Obsidio™ Conformable Embolic
Study Locations (20)
California
- Ronald Reagan UCLA Medical Center - Los Angeles
- St. Joseph's Medical Center - Stockton
Illinois
- Northwestern Memorial Hospital - Chicago
- University of Chicago Hospital - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- Albany Medical Center - Albany
- Mount Sinai Medical Center - New York
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- University of Texas Houston Health Science Center - Houston
Arizona
- Mayo Clinic Hospital - Phoenix
Delaware
- Christiana Hospital - Newark
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2025-09-09 |
What the finished NCT06170619 record still lists
NCT06170619 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 1,479-participant average among 23 other Bleeding trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Obsidio™ Conformable Embolic is the first listed.
NCT06170619 names 20 study sites across 15 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06170619 about?
NCT06170619 is a clinical study titled "Obsidio™ Conformable Embolic Registry". OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
What is the current status of trial NCT06170619?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2024-06-19. Estimated completion is 2025-09-09.
What conditions does trial NCT06170619 study?
This clinical trial studies the following conditions: Bleeding, Hemorrhage, Hypervascular Tumors.
What interventions are being tested in trial NCT06170619?
The interventions under investigation include: Obsidio™ Conformable Embolic (DEVICE).
Who is sponsoring clinical trial NCT06170619?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06170619 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06170619's enrollment target sits among peer trials
125 16th of 23 higher than 8 of 23 other Bleeding trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bleeding trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
RECRUITING
-
Quantra Point-of-Care Hemostasis Monitoring
RECRUITING · NA
-
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
RECRUITING · Phase 4
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI